The future of cell therapy

Research efforts for the last 10 years have been devoted to mitochondrial dysfunction in cancer, which led to evaluating it in neurodegenerative diseases.  This resulted in the discovery and development of Mitochondria Organelle Transplantation (MOT™) technology. We have successfully demonstrated proof of concept for this cellular biotherapy which holds great promise for millions suffering from neurodegenerative diseases such as ALS, Parkinson's and Alzheimer's.

We have exclusive licensing to MOT™ and there is currently no other therapy available like it. Early indications point to much broader applications, that could benefit millions of Americans suffering from various neurodegenerative issues and diseases.